What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce Regeneron Pharmaceuticals, Inc.'s financial and operating results for the fourth quarter and the full fiscal year ended December 31, 2005. It also informs investors about a change in accounting policy regarding stock option compensation.

What is SFAS No. 123 and how does it affect Regeneron's financial reporting?

SFAS No. 123 requires companies to recognize non-cash compensation expense for employee stock options. For Regeneron, this meant that starting January 1, 2005, these expenses were included in operating expenses. This change can lead to a higher reported net loss compared to periods before the adoption, as stock option expense is no longer excluded from operating results.

What are the 'non-GAAP financial measures' mentioned in the filing?

The filing mentions non-GAAP financial measures such as 'pro forma net loss' and specific expense lines (R&D, G&A, contract manufacturing) that have been adjusted to exclude the impact of stock option expense. Management uses these measures to provide what they believe is a clearer view of the company's operational performance and trends, distinct from the impact of accounting standards for stock compensation.

Should investors focus on the GAAP or non-GAAP results?

Investors should review both GAAP and non-GAAP results. GAAP results represent the company's financial performance according to generally accepted accounting principles. Non-GAAP measures, as presented by Regeneron, aim to provide additional insight by isolating the effect of stock option expense, which management believes aids in operational and comparative analysis. It is crucial to look at the reconciliations provided in the press release (Exhibit 99(a)) to understand the differences.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 24, 2006, to announce its financial and operating results for the quarter and full year ended December 31, 2005. A key development noted is the company's adoption of Statement of Financial Accounting Standards No. 123 (SFAS No. 123) effective January 1, 2005, which requires the recognition of non-cash compensation expense for employee stock options. This change impacts reported operating expenses and net loss, as prior periods were not restated. The filing also highlights the use of non-GAAP financial measures, specifically pro forma net loss and various expense categories (R&D, G&A, contract manufacturing) that exclude stock option expense. Regeneron's management believes these non-GAAP measures offer greater transparency and a more useful basis for comparing operating results and for internal financial planning. Investors should review the accompanying press release, incorporated as Exhibit 99(a), for detailed financial data and reconciliations between GAAP and non-GAAP figures.

Key Highlights

1Announcement of Q4 and Full Year 2005 financial and operating results.
2Adoption of SFAS No. 123 effective January 1, 2005, leading to recognition of non-cash stock option expense.
3Prior period operating results were NOT restated for the adoption of SFAS No. 123.
4Use of non-GAAP financial measures, including pro forma net loss, excluding stock option expense.
5Management believes non-GAAP measures provide enhanced transparency and comparability of operating results.
6Press release detailing financial results and GAAP to non-GAAP reconciliations is attached as Exhibit 99(a).

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 24, 2006)

Summary

Key Highlights

Frequently Asked Questions